EFFICACY AND SAFETY OF THE DPP-4 INHIBITOR SAXAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES
- Authors: Demidova T.Y.1, Drozdova I.N.1
-
Affiliations:
- Russian Medical Academy of Postgraduate Education
- Issue: No 4 (2015)
- Pages: 12-23
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/277307
- ID: 277307
Cite item
Open Access
Access granted
Abstract
The increased prevalence of diabetes mellitus (DM) type 2 exceeds all forecasts. The complex pathogenesis of the disease dictates the need for combination therapy. In 2009 a DPP-4 inhibitor with metformin in addition included in the recommendations of the American Association of Clinical Endocrinologists and the American College of Endocrinologists (AACE/ACE) as the first-line treatment of type 2 diabetes (when the level of HbA1 c 6.5-7.5%) and further at all stages of continued therapy as a drug combination therapy. As a result, the set of studies proved the efficacy and safety of saxagliptin and metformin in monotherapy and in combination. Currently, Russia applies a fixed combination of metformin and saxagliptin MB - Kombogliz Prolong. The advantage of this combination is not only a single dose of the drug per day, but with complementary mechanisms of action of saxagliptin and metformin.
Full Text
About the authors
Tatiana Yulievna Demidova
Russian Medical Academy of Postgraduate Education
Email: t.y.demidova@gmail.com
MD, Professor; Professor of the Department of Endocrinology and Diabetology 125315, Moscow, 20 Chasovaya St
Irina Nikolaevna Drozdova
Russian Medical Academy of Postgraduate Educationgraduate student, Department of Endocrinology and Diabetology 125315, Moscow, 20 Chasovaya St
References
- International Diabetes Federation. IDF Diabetes Atlas, 4th ed. Brussels, Belgium: International Diabetes Federation 2009. http://www.idf.org/diabetesatlas, accessed July 6th 2011.
- US Department of Health and Human Services, National Diabetes Information Clearinghouse. National Diabetes Statistics 2007. NIH Publication No. 08-3892. http://diabetes.niddk.nih.gov/dm/pubs/statistics/DM_Statistics.pdf. Last updated: June 2008. Accessed October 19, 2010.
- Narayan K.M., Boyle J.P., Thompson T.J., Sorensen S.W., Williamson D.F. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884-90.
- National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995.
- Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Diabetes Care. 2015;38(1):140-9. doi: 10.2337/dc14-2441.
- Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 7-й вып. М., 2015.
- Drucker D.J. The biology of incretin hormones. Cell. Metab. 2006;3:153-65.
- Kim Y.B., Kopcho L.M., Kirby M.S., Hamann L.G., Weigelt C.A., Metzler W.J., Marcinkeviciene J. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Arch. Biochem. Biophys. 2006;445:9-18.
- Vilsboll T., Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia. 2004;47:357-66.
- Инструкция по медицинскому применению препарата Онглиза с учетом изменений 1-5. Регистрационное удостоверение № ЛСР-008697/10 от 25.08.10.
- Rosenstock J., Sankoh S., List J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes. Metab. 2008;10:5:376-86.
- Rosenstock J., Aguilar-Salinas C., Klein E., Nepal S., List J., Chen R. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr. Med. Res. Opin. 2009;25(10):2401-1 1.
- Nowicki M., Rychlik I., Haller H., Warren M., Suchower L., Gause-Nilsson I., Schützer K.M. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int. J. Clin. Pract. 2011;65(12):1230-9.
- DeFronzo R.A., Hissa M.N., Garber A.J., Luiz Gross J., Yuyan Duan R., Ravichandran S., Chen R.S.; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009;32(9):1649-55.
- Hermans M.P., Delibasi T., Farmer I., Lohm L., Maheux P., Piatti P., Malvolti E., Jörgens S., Charbonnel B. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Curr. Med. Res. Opin. 2012;28(10):1635-45. doi: 10.1 185/03007995.2012.735646.
- Инструкция по медицинскому применению лекарственного препарата Комбоглиз Пролонг с изменениями 1-3. Регистрационное удостоверение ЛП-002068 от 14.05.2013.
- Han S., Iglay K., Davies M.J., Zhang Q., Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr. Med. Res. Opin. 2012;28(6):969-77.
- Schwartz S., Fonseca V., Berner B., Cramer M., Chiang Y.K., Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006;29(4):759-64.
- Fonseca V., Zhu T., Karyekar C., Hirshberg B. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes. Obes. Metab. 2012;14(4):365-71.
- Boulton D.W., Smith C.H., Li L., Huang J., Tang A., LaCreta F.P. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Clin. Drug. Investig. 2011;31(9):619-30.
- C Li.-J., X Liu.-J., Bai L., Yu Q., Zhang Q.-M., Yu P., Yu D.-M. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetology & Metabolic Syndrome 2014,6:69.
- Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998;339:229-34.
- FDA. Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. December 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071627.pdf.
- Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., Ohman P., Frederich R., Wiviott S.D., Hoffman E.B., Cavender M.A., Udell J.A., Desai N.R., Mosenzon O., McGuire D.K., Ray K.K., Leiter L.A., Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013;369(14):1317-26.
- Scirica B.M., Braunwald E., Raz I., Cavender M.A., Morrow D.A., Jarolim P., Udell J.A., Mosenzon O., Im K., Umez-Eronini A.A., Pollack P.S., Hirshberg B., Frederich R., Lewis B.S., McGuire D.K., Davidson J., Steg P.G., Bhatt D.L. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579-88.
- Leiter L.A., Teoh H., Braunwald E., Mosenzon O., Cahn A., Kumar K.M., Smahelova A., Hirshberg B., Stahre C., Frederich R., Bonnici F., Scirica B.M., Bhatt D.L., Raz I. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38:1145-53.
- Fu A.Z. et al. Poster 164-LB, Presented at the 75th Scientific Sessions of the American Diabetes Association, Boston, MA, June 5-9, 2015.
- Schernthaner G., Duran-Garcia S., Hanefeld M., Langslet G., Niskanen L., Östgren C.J., Malvolti E., Hardy E. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes. Obes. Metab. 2015;17(7):630-8. doi: 10.1111/dom.12461. Epub 2015 Apr 7.
Supplementary files
